Karin Stiasny-Kolster Selected Research

Restless Legs Syndrome (Restless Legs)

8/2014	The PD-associated alpha-synuclein promoter Rep1 allele 2 shows diminished frequency in restless legs syndrome.
6/2013	Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany.
8/2011	Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
10/2010	Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study.
9/2010	Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch.
2/2010	Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study.
1/2010	Normal regional brain iron concentration in restless legs syndrome measured by MRI.
12/2008	One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
8/2008	PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome.
7/2008	Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karin Stiasny-Kolster Research Topics

Disease

22	Restless Legs Syndrome (Restless Legs) 08/2014 - 01/2004
6	Parkinson Disease (Parkinson's Disease) 08/2014 - 07/2005
3	REM Sleep Behavior Disorder 04/2013 - 03/2008
2	Nausea 10/2010 - 12/2008
2	Sleepiness 10/2010 - 11/2004
1	Hyperalgesia 08/2013
1	Headache (Headaches) 10/2010
1	Chronic Kidney Failure (Chronic Renal Failure) 12/2008
1	Respiratory Insufficiency (Respiratory Failure) 12/2008
1	Syncope (Fainting) 12/2008
1	Tinnitus 07/2008
1	Iron Deficiencies 01/2007
1	Disorders of Excessive Somnolence (Hypersomnia) 01/2006

Drug/Important Bio-Agent (IBA)

8	rotigotine FDA Link 06/2013 - 12/2004
5	Levodopa (L Dopa)FDA LinkGeneric 08/2013 - 01/2004
5	Dopamine Agonists (Dopamine Agonist)IBA 08/2011 - 12/2004
4	Pharmaceutical PreparationsIBA 04/2013 - 12/2008
4	Dopamine Agents (Dopaminergic Agents)IBA 01/2007 - 01/2004
3	IronIBA 01/2010 - 01/2007
3	Pramipexole (Mirapex)FDA LinkGeneric 01/2007 - 01/2004
2	Biomarkers (Surrogate Marker)IBA 06/2011 - 01/2010
1	alpha-SynucleinIBA 08/2014
1	MotilinIBA 04/2013
1	Pancreatic Polypeptide (Pancreatic Polypeptide (PP))IBA 04/2013
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 06/2011
1	GhrelinIBA 06/2011
1	Anticonvulsants (Antiepileptic Drugs)IBA 12/2008
1	Methadone (Dolophine)FDA LinkGeneric 12/2008
1	Oxycodone (Oxycontin)FDA LinkGeneric 12/2008
1	Dextrans (Dextran)FDA Link 12/2008
1	Tramadol (K315)FDA LinkGeneric 12/2008
1	Valproic Acid (Depakote)FDA LinkGeneric 12/2008
1	Carbamazepine (Tegretol)FDA LinkGeneric 12/2008
1	Opioid Analgesics (Opioids)IBA 12/2008
1	Protein Tyrosine PhosphatasesIBA 08/2008
1	EnzymesIBA 07/2008
1	2- carbomethoxy- 8- (3- fluoropropyl)- 3- (4- iodophenyl)tropaneIBA 03/2008
1	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 02/2008
1	MagnesiumIBA 03/2007
1	Ferritins (Ferritin)IBA 01/2007
1	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 01/2006
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 07/2005
1	Biogenic Amines (Biogenic Amine)IBA 02/2004

Therapy/Procedure

5	Transdermal Patch 06/2013 - 12/2008
3	Therapeutics 01/2007 - 06/2006
1	Aftercare (After-Treatment) 08/2013
1	Drug Therapy (Chemotherapy) 07/2005